英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

Rigel    音标拼音: [r'ɑɪdʒəl]

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Rigel Pharmaceuticals, Inc. (RIGL)
    Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer
  • Pipeline :: Rigel Pharmaceuticals, Inc. (RIGL)
    Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases
  • Investor Relations :: Rigel Pharmaceuticals, Inc. (RIGL)
    Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases
  • Rigel Provides Business Update and 2025 Outlook
    Rigel continues to advance its Phase 1b clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of R289 in patients with relapsed or refractory (R R) lower-risk myelodysplastic syndrome (MDS)
  • Rigel Reports First Quarter 2025 Financial Results and Provides . . .
    Rigel continues to advance its Phase 1b clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of R289 in patients with relapsed or refractory (R R) lower-risk MDS
  • Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting . . .
    Rigel's poster presentations will include data for GAVRETO ® (pralsetinib) for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), including final data from the Phase 1 2 ARROW study, and REZLIDHIA ® (olutasidenib) for the treatment of relapsed or refractory (R R) mutated
  • Rigel Announces R289 Granted Fast Track Designation by the FDA for . . .
    R289 1, Rigel's potent and selective dual inhibitor of IRAK1 and IRAK4, is being studied in an ongoing Phase 1b study evaluating the safety, tolerability, pharmacokinetics and preliminary activity in patients with LR-MDS who are relapsed or refractory to prior therapies
  • Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for . . .
    SOUTH SAN FRANCISCO, Calif , Oct 24, 2024 PRNewswire -- Rigel Pharmaceuticals, Inc ("Rigel") (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced it is issuing a Dear Health Care Provider (DHCP) letter related to a new safety signal for GAVRETO ® (pralsetinib) after
  • Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib . . .
    "The resolution of this patent litigation underscores the strength of Rigel's intellectual property protecting TAVALISSE, an innovative treatment for people with immune thrombocytopenia," said Raul Rodriguez, Rigel's president and CEO
  • Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS
    R289 1, Rigel's potent and selective dual inhibitor of IRAK1 and IRAK4, is being studied in an ongoing Phase 1b study evaluating the safety, tolerability, pharmacokinetics and preliminary activity in patients with LR-MDS who are relapsed or refractory to prior therapies





中文字典-英文字典  2005-2009